NYSEAMERICAN : LCTX

Lineage Cell Therapeutics, Inc. — Key statistics

Healthcare · Biotechnology · United States

Last price 1 USD (Oct 30, 2026, 10:19 AM EDT) · Market cap 252.91M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Key statistics

Valuation

Measure	Value
Market Cap	252.91M
Enterprise Value	204.38M

Dates

Measure	Value
Earnings Date	Nov 13, 2026
Ex-Dividend Date	n/a

Shares

Measure	Value
Current Share Class	252.91M
Shares Outstanding	252.91M
Shares Change (YoY)	+8.73%
Shares Change (QoQ)	+0.11%
Owned by Insiders (%)	4.86%
Owned by Institutions (%)	26.86%
Float	191.06M

Ratios

Measure	Value
PE Ratio	n/a
Forward PE	n/a
PS Ratio	19.33
Forward PS	16.41
PB Ratio	4.15
P/TBV Ratio	13.64
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Evratios

Measure	Value
EV / Earnings	n/a
EV / Sales	15.62
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financialposition

Measure	Value
Current Ratio	6.61
Quick Ratio	6.46
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financialefficiency

Measure	Value
Return on Equity (ROE)	-60.06%
Return on Assets (ROA)	-17.04%
Return on Invested Capital (ROIC)	-238.29%
Return on Capital Employed (ROCE)	-27.34%
Weighted Average Cost of Capital (WACC)	12.95%
Revenue Per Employee	$169,909
Profits Per Employee	-$418,961
Employee Count	77
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

Measure	Value
Income Tax	-5.28M
Effective Tax Rate	n/a

Stockprice

Measure	Value
Beta (5Y)	1.60
52-Week Price Change	-41.52%
50-Day Moving Average	1.02
200-Day Moving Average	1.33
Relative Strength Index (RSI)	50.83
Average Volume (20 Days)	1,397,480

Shortselling

Measure	Value
Short Interest	25.93M
Short Previous Month	29.47M
Short % of Shares Out	10.25%
Short % of Float	13.57%
Short Ratio (days to cover)	15.40

Incomestatement

Measure	Value
Revenue	13.08M
Gross Profit	-7.51M
Operating Income	-26.85M
Pretax Income	-37.39M
Net Income	-32.26M
EBITDA	-26.11M
EBIT	-26.85M
Loss Per Share	-$0.19

Balancesheet

Measure	Value
Cash & Cash Equivalents	50.83M
Total Debt	2.30M
Net Cash	48.53M
Net Cash Per Share	$0.19
Equity (Book Value)	59.80M
Book Value Per Share	0.24
Working Capital	44.95M

Cashflow

Measure	Value
Operating Cash Flow	-23.82M
Capital Expenditures	-574,000
Depreciation & Amortization	739,000
Net Borrowing	-54,000
Free Cash Flow	-24.39M
FCF Per Share	-$0.10

Margins

Measure	Value
Gross Margin	-57.36%
Operating Margin	-205.23%
Pretax Margin	-285.75%
Profit Margin	-246.58%
EBITDA Margin	-199.58%
EBIT Margin	-205.23%
FCF Margin	n/a

Dividends

Measure	Value
Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
FCF Payout Ratio	n/a
Buyback Yield	-8.73%
Shareholder Yield	-8.73%
Earnings Yield	-18.55%
FCF Yield	-9.64%

Analystforecasts

Measure	Value
Price Target	$5.50
Price Target Difference	450.00%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (3Y)	60.09%
EPS Growth Forecast (3Y)	n/a

Stocksplits

Measure	Value
Last Split Date	Oct 31, 1997
Split Type	Forward
Split Ratio	3:1

Scores

Measure	Value
Altman Z-Score	-1.77
Piotroski F-Score	3

Fairvalue

Measure	Value
Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a